

Tumor therapeutics work as stress inducers to enhance tumor sensitivity to NK cell cytotoxicity by upregulating NKp30 ligand B7-H6

Guoshuai Cao[‡], Jian Wang^{‡1}, Xiaodong Zheng[‡], Haiming Wei^{‡||}, Zhigang Tian^{‡||}, Rui Sun^{‡§||1}

[‡]Institute of Immunology, Key Laboratory of Innate Immunity and Chronic Disease of Chinese Academy of Science, School of Life Sciences and Medical Center, University of Science and Technology of China, Hefei, Anhui 230027, China

[§]State Key Laboratory of Cellular Stress Biology, Innovation Center for Cell Signaling Network, School of Life Sciences, Xiamen University, Xiamen, Fujian 361005, China

^{||}Hefei National Laboratory for Physical Sciences at Microscale, Hefei, Anhui 230027, China

***Running title:** *Tumor therapeutics enhance B7-H6 expression on tumor cells*

¹To whom correspondence may be addressed: Department of Immunology, School of Life Sciences, University of Science and Technology of China, Hefei, Anhui 230027, China. Tel.: +86-551-6360-7377; Fax: +86-551-6360-0832; E-mail: sunr@ustc.edu.cn; ustcwj@mail.ustc.edu.cn.

Keywords: B7-H6, tumor cells, tumor therapeutics, NK cell, NKp30

Capsule

Background: B7-H6, the ligand for NKp30, is expressed on tumor cells.

Results: Tumor therapeutics promote B7-H6 expression in tumor cells and enhance tumor sensitivity to NK cell cytotoxicity.

Conclusion: Tumor therapeutics work as stress inducers to enhance tumor sensitivity to NK cell cytotoxicity.

Significance: These results suggest that B7-H6 could be a potential target for tumor therapy in the future.

showed that treatment of tumor cells with almost all standard tumor therapeutics, including chemotherapy (cisplatin, 5-fluorouracil), radiation therapy, non-lethal heat shock, and cytokine therapy (TNF- α), could upregulate the expression of B7-H6 in tumor cells and enhance tumor sensitivity to NK cell cytotoxicity. B7-H6 shRNA treatment effectively dampened sensitization of tumor cells to NK-mediated lysis. Our study not only reveals the possibility that tumor therapeutics work as stress inducers to enhance tumor sensitivity to NK cell cytotoxicity but also suggests that B7-H6 could be a potential target for tumor therapy in the future.

Abstract

Immune cells are believed to participate in initiating anti-tumor effects during regular tumor therapy such as chemotherapy, radiation, hyperthermia and cytokine injection. One of the mechanisms underlying this process is the expression of so-called stress-inducible immunostimulating ligands. Although the activating receptor NKG2D has been proven to play roles in tumor therapy through targeting its ligands, the role of NKp30, another key activating receptor, is seldom addressed. In this study, we found that the NKp30 ligand B7-H6 was widely expressed in tumor cells and closely correlated to their susceptibility to NK cell lysis. Further studies

Introduction

Increasing evidence supports the notion that complete remission of tumors relies on eliciting endogenous anti-tumor immunity (1, 2). Appropriate chemotherapy, radiation therapy, hyperthermia therapy and immunotherapy have been proven to break the immunosuppressive state at the tumor location and activate anti-tumor immune effects. Tumor therapy elicits endogenous anti-tumor immune responses via various mechanisms including promoting the activation of NK cells and tumor-specific CTLs (3-5). However, although NK cells have been proven vital in initiating the anti-tumor response and are extensively applied in tumor treatments (6-9), the

mechanisms by which NK cells are activated in tumor treatments remain largely unexplored.

The balance of activating receptors and inhibitory receptors manipulates the activation of NK cells. Activating receptors mainly include C-type lectin like receptors NKG2D, natural cytotoxicity receptors including NKp30, NKp44, and NKp46, as well as activating members of the Ly49 family(6). Upregulation of NKG2D ligands on tumor cells mediated by tumor therapy-induced cell stress has been extensively studied. For example, the DNA damage response induced by irradiation and chemotherapeutic reagents is reported to upregulate the expression of NKG2D ligands on tumor cells(10). Non-lethal heat shock, mimicking hyperthermia therapy, increases the expressions of Mult-1(11), MICA and MICB on tumor cells(12). Among the cytokines used for immunotherapy, TNF- α has been shown to induce the expression of MICA in human primary tissue cells and tumor cells(13, 14).

NKp30 is another important activating receptor expressed on NK cells(15, 16), and increasing the expression of NKp30 ligands on tumor cells may represent another approach to tumor therapy using NK cells. B7-H6, the only membrane-binding ligand among the three known NKp30 ligands, is widely expressed on tumor cells but not healthy tissue cells (17-19), implying that B7-H6 may be a useful target for tumor therapy. However, regulation of B7-H6 expression on tumor cells by tumor therapy-induced cell stress remains elusive.

In this study, we investigated the influence of tumor therapy on B7-H6 expression on tumor cells and found that chemotherapy, radiation therapy, hyperthermia therapy, and immunotherapy could increase B7-H6 expression on tumor cells. When subjected to NK cell-mediated cytotoxicity, target cells exposed to tumor therapy were more sensitive to NK cell lysis when compared with untreated cells. Moreover, lentivirus-delivered B7-H6-specific shRNA treatment reduced the sensitivity of tumor cells to NK cell lysis, implying that increased B7-H6 expression contributed to tumor sensitization to NK cell cytotoxicity. Thus, our findings showed that tumor therapeutics work as stress inducers to enhance tumor sensitivity to NK cell cytotoxicity, suggesting that increasing the expression of B7-H6 on tumor cells may be a promising approach for tumor therapy.

Materials and Methods

Cells, radiation and heat shock

NK-92 cells were purchased from the ATCC (American Type Culture Collection) and maintained in MEM- α containing 12.5% FBS, 12.5% horse serum, 100 IU/ml IL-2 (Changsheng, Changchun, China), 0.2 mM inositol, 0.02 mM folic acid and 2-ME. NKG cells were generated in our laboratory(20) and maintained in MEM- α containing 10% FBS, 10% horse serum, 100 IU/ml IL-2. HEK293 (human embryonic kidney epithelial cell), HepG2 (hepatocellular carcinoma), SK-LU-1 (lung adenocarcinoma) and HeLa (cervical carcinoma) cells were maintained in DMEM containing 10% FBS. U937 (acute myeloid leukemia), H7402 (hepatocarcinoma), H460 (lung carcinoma) and Ho8910 (ovarian carcinoma) cells were maintained in RPMI-1640 medium containing 10% FBS. K562 (chronic myeloid leukemia) and HL60 (acute myeloid leukemia) were maintained in IMDM containing 10% FBS. A549 (lung carcinoma) and Du145 (prostate carcinoma) cells were maintained in F-12 medium containing 10% FBS. Huh-7 (hepatocarcinoma) cells were maintained in DMEM containing 15% FBS. All cells were passaged every 2-3 days. For irradiation, HEK293 cells were diluted to a concentration of 1×10^6 /ml and irradiated with ^{137}Cs at a dose rate of 100 cGy/min. For non-lethal heat-shock treatment, cells were diluted to a concentration of 1×10^6 /ml and exposed to 42°C for 30 min.

Reagents

Anti-B7-H6 polyclonal serum was generated by immunizing rabbits with recombinant B7-H6 (25-260 AA)-6His. B7-H6 antibody was purified with Protein A Sepharose (GE) and then with B7-H6-6His coupled CNBr-activated Sepharose (GE). 5-Fluorouracil (5-FU) was purchased from Sigma. Cisplatin injection was obtained from Nanjing Pharmaceutical Factory Co., Ltd. TNF- α was purchased from PeproTech. FITC-goat anti-mouse IgG were purchased from Santa Cruz and 647-goat anti-rabbit IgG were purchased from Invitrogen. The blocking antibody anti-NKp30 (final concentration 1ng/ml), anti-NKG2D (final concentration 2ng/ml) and control mouse IgG (final concentration 3ng/ml) were purchased from BioLegend.

Quantitative RT-PCR

Total RNA was isolated using TRIzol reagent (Invitrogen) according to the manufacturer's

protocol. RNA was reverse transcribed using M-MLV reverse transcriptase (Invitrogen), and the resulting cDNA was used for quantitative PCR. SYBR Premix Ex Taq II (Takara) was for quantitative PCR. The cycling parameters were 95°C for 30 s, followed by 40 cycles of 95°C for 5 s and 60°C for 30 s. The following primers were used:

B7-H6-F, 5'-TTTTCATTTCATTGGTGGCCTA-3'; B7-H6-R, 5'-TGCCCGAGTGCAAAAGAATATG-3'; β -actin-F, 5'-CTGGAACGGTGAAGGTGACA-3'; and β -actin-R, 5'-AAGGGACTTCCTGTACAATGCA-3'.

Western blotting

Cells were washed twice with ice-cold PBS and then lysed in RIPA Lysis Buffer (Beyotime) supplemented with 0.25 mg/ml PMSF (Sigma), 1× protease inhibitor (Roche). An equal volume of 2× sample loading buffer (62.5 mM Tris-HCl, 25% glycerol, 2% SDS, 0.02% bromophenol blue, 5% β -mercaptoethanol, pH 6.8) was added, and cleared extracts were frozen at -80°C. The protein concentration was determined using the Bradford method (Bio-Rad). Equal amounts of protein were denatured, electrophoresed, and blotted. For chemiluminescence, HRP-conjugated secondary antibodies (Boster) were applied, and ECL substrate (Bio-Rad) was used for detection.

Construction of expression vectors

B7-H6 expression vector was constructed by inserting B7-H6 coding sequence into pcDNA 3.0 plasmid. For myc-B7-H6 expression vector, human CD8a signal peptide sequence (ATGGCCTTACCAGTGACCGCCTTGCTCCTGCCGCTGGCCTTGCTGCTCCACGCCGCCAGG) and three tandem myc-tag sequence (GAACAA AACTC ATCCTA GAAGAG GATCTG) fused at N-terminal with B7-H6 coding sequence excluding signal peptide sequence were inserted into pcDNA 3.0 plasmid. Both expression vectors were validated by DNA sequencing.

Lentiviral construction and transduction of cells

shB7-H6-1 segments (top, 5'-CGCGTGGCCTGCTCTCCTAACAGTTTTCAGAGAACTGTTAGGAGAGCAGGGTTTAT-3'; bottom, 5'-CGATAAAACCCTGCTCTCCTAACAGTTTCTCTGAAACTGTTAGGAGAGCAGGGCA-3'), shB7-H6-2 segments (top, 5'-CGCGTGGTCTACCCAGAGGCTATTCAGAGATAGCCTCTGGGTAGAACCTTTTAT-3'; bottom, 5'-

CGATAAAAGGTTCTACCCAGAGGCTATCTCTTGAATAGCCTCTGGGTAGAACCA-3') and shScr were inserted into the pLVTHM vector with the *Cl* and *Mlu*I restriction sites. Lentiviral supernatants were generated by co-transfecting 293T cells with pLVTHM, psPAX2 and pMD2G plasmids using Lipofectamine 2000 reagent (Invitrogen). Culture supernatants collected 36 h after transfection were added directly to cells plated in 6-well culture plates, and Polybrene (Sigma) was added at a final concentration of 5 μ g/ml for 24 h. Transduced cells were characterized by GFP expression.

Cytotoxicity assay

NK-92 cells were used as effector cells and co-cultured with target cells at specific ratios for 4 h, and cytotoxicity was determined using the CytoTox 96 Non-Radioactive Cytotoxicity Assay (Promega). The data shown represent at least three independent experiments.

Statistical analysis

Results were analyzed using two-tailed Student's *t*-tests. The data were expressed as the mean $\pm$ standard error of the mean (SEM). Values of $P < 0.05$ were considered statistically significant. Significance was denoted as * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$.

Results

B7-H6 is widely expressed in tumor cells. To investigate the expression of B7-H6 in tumor cells, anti-B7-H6 polyclonal antibody was generated in our laboratory due to the lack of appropriate commercial antibody. The stained bands could only be detected in B7-H6 transfection group but not in untreated group and control vector group in CHO-K1 and HEK293 cells (Fig. 1A, 1B), suggesting that the anti-B7-H6 antibody was specific and suitable for Western blotting analysis of B7-H6 expression in cells, which was further confirmed by myc-B7-H6 transfection and staining in HEK293 cell (Fig. 1B). Furthermore, the B7-H6 antibody was also suitable for flow cytometry, which was determined by comparing the expressions of B7-H6 and myc-B7-H6 on cell surface detected by anti-B7-H6 antibody and anti-myc antibody, respectively (Fig. 1C, 1D). Thus, the anti-B7-H6 polyclonal antibody was generated in our laboratory was specific and suitable for B7-H6 expression analysis by Western blotting and flow cytometry.

Next, to evaluate whether B7-H6 could be a potential target for tumor therapy to activate NK cells, the expression of B7-H6 was examined by real-time PCR and Western blotting in 12 tumor cell lines derived from leukemia, hepatocarcinoma, lung carcinoma, cervical carcinoma, ovarian carcinoma and prostate carcinoma. B7-H6 expression was detected in all tumor cell lines, although the level of expression varied among the cell lines (Fig. 2A, 2B). Moreover, more than one band could be detected using the B7-H6 antibody in some tumor cell lines (Fig. 2B), suggesting that there were differential post-translational modifications of B7-H6, which is consistent with a previous study (21). Thus, these data suggested that B7-H6 was extensively expressed in tumor cells.

B7-H6 expressed in tumor cells correlates with their susceptibility to NK cell lysis. To evaluate the impact of B7-H6 expression on tumor sensitivity to NK cell-mediated lysis, B7-H6 expression in tumor cell lines were silenced with shRNA. In order to avoid the off-target effects of shRNA, we used two shB7-H6 sequences, shB7-H6-1 and shB7-H6-2, to treat tumor cells. shRNA treatment effectively downregulated the B7-H6 expression at mRNA and protein levels (Fig. 3A, 3B) and reduced the killing activity of NK-92 cells to target cells HEK293 (Fig. 3C), suggesting that the shRNA was effective. Furthermore, knockdown of B7-H6 expression increased the resistance of tumor cell lines, including leukemia (K562, HL60 and U937) and cervical adenocarcinoma (HeLa), to lysis by NK-92 cells (Fig. 3D). Thus, these data suggest that the level of B7-H6 expression in tumor cells correlates with their susceptibility to NK cell lysis.

Chemotherapy upregulates B7-H6 expression in tumor cells and enhances tumor sensitivity to NK cell cytotoxicity. Chemotherapy, including treatment with cisplatin or 5-FU, has been proven effective in certain cancer treatments. To explore whether chemotherapy could increase the sensitivity of tumor cells to NK cell lysis by promoting B7-H6 expression, HEK293 cells were treated with chemotherapy reagents. And B7-H6 expression was then analyzed by real-time PCR, Western blotting and Flow cytometry. Treatment with cisplatin (Fig. 4A-D) or 5-FU (Fig. 5A-D) increased the expression of B7-H6 at mRNA and protein levels as well as on the cell surface. Similarly, leukemia HL60 cells with low B7-H6 expression upregulated B7-H6 expressions at both

protein level and cell surface after cisplatin or 5-FU treatment (Fig. 4E-F, Fig. 5E-F). Cisplatin or 5-FU treatment caused the tumor cells to become more sensitive to NK-92-mediated killing (Fig. 4G and 5G). Silencing B7-H6 expression in target cells significantly decreased NK cell mediated cytotoxicity (Fig. 4H and 5H). Thus, these data suggest that chemotherapy could promote the expression of B7-H6 in tumor cells and thereby increase the sensitivity of tumor cells to NK cell lysis.

Irradiation increases B7-H6 expression and makes target cells more sensitive to NK cell cytotoxicity. Radiation therapy has been reported to contribute to eliciting the anti-tumor immune response(22). HEK293 cells were treated with γ -irradiation, and then B7-H6 expression was analyzed by real-time PCR, Western blotting and Flow cytometry. Irradiation increased the B7-H6 expression at mRNA and protein levels in a time- and dose-dependent manner (Fig. 6A-D). The expression of B7-H6 on cell surface was also increased upon irradiation (Fig. 6E). Similar results were obtained in HL60 cells upon irradiation (Fig. 6F-H). Importantly, the irradiation-treated tumor cells became more sensitive to NK cell lysis when co-cultured with the NK-92 cell line (Fig. 6I). Treating with B7-H6 shRNA before irradiation significantly decreased the sensitivity of the HEK293 cell to NK cell lysis (Fig. 6J). These data thus suggest that irradiation could increase the expression of B7-H6 in tumor cells and that B7-H6 was involved in making tumor cells more sensitive to lysis by NK cells.

Heat shock increases B7-H6 expression and makes target cells more sensitive to NK cell cytotoxicity. To evaluate whether hyperthermia could affect tumor sensitivity to NK cells in a B7-H6-dependent manner, HEK293 cells were exposed to non-lethal heat shock by incubation at 42°C for 30 min. Heat shock treatment caused a transient upregulation of B7-H6 mRNA (Fig. 7A) and protein (Fig. 7B), peaking at 9 h and 12 h post treatment, respectively, and declined quickly thereafter. Further flow cytometry analysis displayed that B7-H6 expression on cell surface increased upon heat shock treatment (Fig. 7C). Heat shock treatment also promoted B7-H6 expression in HL60 cells (Fig. 7D, 7E). When subjected to NK-92-mediated lysis, HEK293 cells exposed to heat shock treatment became more sensitive to NK cell lysis (Fig. 7F). Treatment with B7-H6 shRNA before heat-shock treatment

significantly decreased the sensitivity of the HEK293 cells to NK cell lysis (Fig. 7G). These data thus suggest that hyperthermia may enhance the sensitivity of tumor cells to NK cell lysis by upregulating B7-H6 expression.

Cytokine treatment increases B7-H6 expression and sensitizes target cells to NK cell cytotoxicity. Localized administration of TNF- α has been demonstrated to be effective in controlling tumor growth(23). To explore whether TNF- α treatment would directly affect B7-H6 expression in tumor cells, HEK293 cells were stimulated with TNF- α , and B7-H6 expression was then analyzed by real-time PCR, Western blotting and Flow cytometry. TNF- α treatment increased the expression of B7-H6 at mRNA and protein levels as well as on cell surface (Fig. 8A-E). Similar results were also acquired in HL60 cells after TNF- α treatment (Fig. 8F-H). Moreover, TNF- α treatment increased tumor cell sensitivity to NK cell lysis (Fig. 8I). B7-H6 shRNA treatment significantly decreased the sensitivity of the HEK293 cells to NK cell lysis (Fig. 8J). Thus, these data suggest that TNF- α treatment could enhance the sensitivity of tumor cells to NK cell lysis by upregulating B7-H6 expression.

Enhancing tumor sensitivity to NK cell cytotoxicity by tumor therapeutics depends on the combined action of NKG2D and NKp30 signals. NKG2D ligands have been reported to be upregulated upon tumor therapy and contribute to tumor sensitization to NK cell cytotoxicity. To validate our proposal that increased B7-H6 expression induced by tumor therapeutics also participate in tumor sensitivity to NK cell cytotoxicity, anti-NKp30 and anti-NKG2D blocking antibodies were used during cytotoxicity. Blocking NKp30 or NKG2D function alone dampened NK cell-mediated cytotoxicity to tumor cells, while simultaneously blocking both receptors lead to the least cytotoxicity (Fig. 9A-C). Thus, these data suggest that enhancing tumor sensitivity to NK cell cytotoxicity upon tumor therapy depended on not only increase of NKG2D ligands but also increase of NKp30 ligand B7-H6 on tumor cells.

Discussion

In many cases, an intact immune system is essential for complete remission during tumor therapy (1, 2). Deficiency of immune-related molecules or cells dampens the efficacy of conventional tumor therapy(22, 24). Studies have

shown that in successful tumor treatments, including radiation therapy(3, 22, 25, 26), hyperthermia therapy(4) and chemotherapy(5, 27-29), endogenous anti-tumor immunity is elicited and is demonstrably effective. Recently, the success of PD-1 and PD-L1 antibodies in combating tumors has provided support for the notion that endogenous anti-tumor immunity participates in tumor elimination(30, 31).

Tumor-specific CTLs, as the effector cells with the strongest anti-tumor effects, have been extensively investigated. Studies have revealed that CD8⁺ T cells are indispensable for tumor elimination in certain murine tumor models(3, 32). Tumor-specific CTLs induced by appropriate tumor therapy mediate the anti-tumor effects not only locally but also at distal sites(3-5, 22). However, although CTLs play a critical role in the elimination of tumor cells, the functions of other immune cells, such as innate immune cell NK cells(9), cannot be neglected in this process.

NK cells have been shown to participate in tumor immunosurveillance in humans and mice (6). Low-dose radiation administered to NK cells directly enhances their cytotoxic ability without changing their phenotype(33, 34). Tumor therapy also promotes NK activation via DAMPs released from destroyed cells(25). NK cells mediate tumor cytotoxicity directly via perforin and granzymes or indirectly by inducing tumor apoptosis via death receptors (FasL and TRAIL). IFN- γ secreted by activated NK cells promotes Th1 cell polarization and induces tumor-specific CTLs (15, 16).

NK cell activation is regulated by activating receptors and inhibitory receptors(35). The NK cell activating receptor NKG2D has been proved indispensable in several murine tumor models(36, 37). Regulation of NKG2D ligand expression on tumor cells has been extensively studied. γ -Radiation, cisplatin therapy, and 5-FU therapy upregulate the expression of the NKG2D ligands MICA and ULBP-1,2,3 on tumor cells in humans(12). NKp30 is another important activating receptor of NK cells, but compared with NKG2D, study of NKp30 has lagged behind. Nonetheless, in vitro studies have demonstrated that NKp30 is involved in tumor elimination(38).

NKp30 ligands include MCMV protein pp65, nuclear protein BAT3, and B7-H6 (17-19). However, B7-H6 is the only transmembrane ligand of NKp30. Most importantly, B7-H6 is

selectively expressed on tumor cells under steady-state conditions(39), implying that the interaction between NKp30 and B7-H6 may be involved in promoting the activation of NK cells and mediating the NK cell lysis of tumor cells. It has been reported that B7-H6 is downregulated by HDAC inhibitor(40). In this study, we found that B7-H6 was widely expressed in tumor cells, and B7-H6 expression levels in tumor cells correlated to their susceptibility to NK cell lysis. Further studies showed that almost all tumor therapies could work as stress inducers to upregulate the expression of B7-H6 in tumor cells.

Although we have found that tumor therapies can upregulate the expression of B7-H6 in tumor cells, the underlying mechanisms that regulate the expression of B7-H6 remain unknown. Based on previous studies, we speculate that treatment with irradiation, cisplatin or 5-FU induces the DNA damage response and treatment with TNF- α activates the NK- κ B signaling pathway, thereby potentially increasing the expression of B7-H6 in tumor cells. Further studies about the mechanisms underlying B7-H6 expression are needed.

Acknowledgments: This work was supported by the Ministry of Science & Technology of China (973 Basic Science Project, 2013CB530506), Natural Science Foundation of China (#91029303), National Science & Technology Major Projects (2012ZX10002014), and the National High Technology Research & Development Program (863 program, 2012AA020901).

Conflict of interest: The authors declare that they have no conflicts of interest with the contents of this article.

Author contributions: Conceived and designed the experiments: GC, JW, ZT, and RS. Performed the experiments: GC. Analyzed the data: GC, JW, ZT, and RS. Contributed reagents/materials/analysis tools: XZ and HW. Wrote the manuscript: GC, JW, ZT, and RS. All authors analyzed the results and approved the final version of the manuscript.

REFERENCES

- (1) Zitvogel, L., Apetoh, L., Ghiringhelli, F., xE, ois, Andr, xE, Fabrice, Tesniere, A., and Kroemer, G. (2008) The anticancer immune response: indispensable for therapeutic success? *The Journal of Clinical Investigation*. **118**, 1991-2001
- (2) Zitvogel, L., Kepp, O., and Kroemer, G. (2011) Immune parameters affecting the efficacy of chemotherapeutic regimens. *Nat Rev Clin Oncol*. **8**, 151-160
- (3) Takeshima, T., Chamoto, K., Wakita, D., Ohkuri, T., Togashi, Y., Shirato, H., Kitamura, H., and Nishimura, T. (2010) Local Radiation Therapy Inhibits Tumor Growth through the Generation of Tumor-Specific CTL: Its Potentiation by Combination with Th1 Cell Therapy. *Cancer Research*. **70**, 2697-2706
- (4) Toraya-Brown, S., Sheen, M.R., Zhang, P., Chen, L., Baird, J.R., Demidenko, E., Turk, M.J., Hoopes, P.J., Conejo-Garcia, J.R., and Fiering, S. (2014) Local hyperthermia treatment of tumors induces CD8+ T cell-mediated resistance against distal and secondary tumors. *Nanomedicine: Nanotechnology, Biology and Medicine*. **10**, 1273-1285
- (5) Tarnowski, G.S., Faanes, R.B., Ralph, P., and Williams, N. (1978) Suppression and Restoration of Cytotoxic T-Cell Activity during Chemotherapy of a Mouse T-Cell Lymphoma and a Macrophage Tumor. *Cancer Research*. **38**, 4540-4545
- (6) Vivier, E., Raulet, D.H., Moretta, A., Caligiuri, M.A., Zitvogel, L., Lanier, L.L., Yokoyama, W.M., and Ugolini, S. (2011) Innate or Adaptive Immunity? The Example of Natural Killer Cells. *Science*. **331**, 44-49
- (7) MORETTA, L., Pietra, G., Montaldo, E., Vacca, P., Pende, D., Falco, M., Del Zotto, G., Locatelli, F., Moretta, A., and Mingari, M.C. (2014) HUMAN NK CELLS: FROM SURFACE RECEPTORS TO THE THERAPY OF LEUKEMIAS AND SOLID TUMORS. *Frontiers in Immunology*. **5**,

- (8) Cheng, M., Chen, Y., Xiao, W., Sun, R., and Tian, Z. (2013) NK cell-based immunotherapy for malignant diseases. *Cell Mol Immunol.* **10**, 230-252
- (9) Childs, R.W., and Carlsten, M. (2015) Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer: the force awakens. *Nat Rev Drug Discov.* **advance online publication**,
- (10) Gasser, S., Orsulic, S., Brown, E.J., and Raulet, D.H. (2005) The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. *Nature.* **436**, 1186-1190
- (11) Nice, T.J., Coscoy, L., and Raulet, D.H. (2009) Posttranslational regulation of the NKG2D ligand Mult1 in response to cell stress. *The Journal of Experimental Medicine.* **206**, 287-298
- (12) Venkataraman, G.M., Suci, D., Groh, V., Boss, J.M., and Spies, T. (2007) Promoter Region Architecture and Transcriptional Regulation of the Genes for the MHC Class I-Related Chain A and B Ligands of NKG2D. *The Journal of Immunology.* **178**, 961-969
- (13) Jinushi, M., Takehara, T., Kanto, T., Tatsumi, T., Groh, V., Spies, T., Miyagi, T., Suzuki, T., Sasaki, Y., and Hayashi, N. (2003) Critical Role of MHC Class I-Related Chain A and B Expression on IFN- α -Stimulated Dendritic Cells in NK Cell Activation: Impairment in Chronic Hepatitis C Virus Infection. *The Journal of Immunology.* **170**, 1249-1256
- (14) Lin, D., Lavender, H., Soilleux, E.J., and O'Callaghan, C.A. (2012) NF- κ B Regulates MICA Gene Transcription in Endothelial Cell through a Genetically Inhibitable Control Site. *Journal of Biological Chemistry.* **287**, 4299-4310
- (15) Vitale, M., Chiesa, M.D., Carlomagno, S., Pende, D., Aricò, M., Moretta, L., and Moretta, A. (2005) NK-dependent DC maturation is mediated by TNF α and IFN γ released upon engagement of the Nkp30 triggering receptor. *Blood.* **106**, 566-571
- (16) Morandi, B., Mortara, L., Chiossone, L., Accolla, R.S., Mingari, M.C., Moretta, L., Moretta, A., and Ferlazzo, G. (2012) Dendritic Cell Editing by Activated Natural Killer Cells Results in a More Protective Cancer-Specific Immune Response. *PLoS ONE.* **7**, e39170
- (17) Arnon, T.I., Achdout, H., Levi, O., Markel, G., Saleh, N., Katz, G., Gazit, R., Gonen-Gross, T., Hanna, J., Nahari, E., Porgador, A., Honigman, A., Plachter, B., Mevorach, D., Wolf, D.G., and Mandelboim, O. (2005) Inhibition of the Nkp30 activating receptor by pp65 of human cytomegalovirus. *Nat Immunol.* **6**, 515-523
- (18) Pogge von Strandmann, E., Simhadri, V.R., von Tresckow, B., Sasse, S., Reiners, Katrin S., Hansen, H.P., Rothe, A., Böll, B., Simhadri, V.L., Borchmann, P., McKinnon, P.J., Hallek, M., and Engert, A. (2007) Human Leukocyte Antigen-B-Associated Transcript 3 Is Released from Tumor Cells and Engages the Nkp30 Receptor on Natural Killer Cells. *Immunity.* **27**, 965-974
- (19) Brandt, C.S., Baratin, M., Yi, E.C., Kennedy, J., Gao, Z., Fox, B., Haldeman, B., Ostrander, C.D., Kaifu, T., Chabannon, C., Moretta, A., West, R., Xu, W., Vivier, E., and Levin, S.D. (2009) The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor Nkp30 in humans. *The Journal of Experimental Medicine.* **206**, 1495-1503
- (20) Cheng, M., Ma, J., Chen, Y., Zhang, J., Zhao, W., Zhang, J., Wei, H., Ling, B., Sun, R., and Tian, Z. (2011) Establishment, Characterization, and Successful Adaptive Therapy Against Human Tumors of NKG Cell, a New Human NK Cell Line. *Cell Transplantation.* **20**, 1731-1746
- (21) Schlecker, E., Fiegler, N., Arnold, A., Altevogt, P., Rose-John, S., Moldenhauer, G., Sucker, A., Paschen, A., von Strandmann, E.P., Textor, S., and Cerwenka, A. (2014) Metalloprotease-Mediated Tumor Cell Shedding of B7-H6, the Ligand of the Natural Killer Cell-Activating Receptor Nkp30. *Cancer Research.* **74**, 3429-3440
- (22) Lee, Y., Auh, S.L., Wang, Y., Burnette, B., Wang, Y., Meng, Y., Beckett, M., Sharma, R., Chin, R., Tu, T., Weichselbaum, R.R., and Fu, Y.-X. (2009) Therapeutic effects of ablative radiation on local tumor require CD8 $^{+}$ T cells: changing strategies for cancer treatment. *Blood.* **114**, 589-595
- (23) Manusama, E.R., Stavast, J., Durante, N.M.C., Marquet, R.L., and Eggermont, A.M.M. (1996) Isolated limb perfusion with TNF α and melphalan in a rat osteosarcoma model: a new anti-tumour approach. *European Journal of Surgical Oncology (EJSO).* **22**, 152-157
- (24) Apetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Maiuri, M.C., Ullrich, E., Saulnier, P., Yang, H., Amigorena, S., Ryffel, B., Barrat, F.J., Saftig, P., Levi, F., Lidereau, R., Nogues, C., Mira, J.-P., Chompret, A., Joulin, V., Clavel-Chapelon, F., Bourhis, J., Andre, F., Delaloge, S., Tursz, T., Kroemer, G., and Zitvogel, L. (2007) Toll-like receptor 4-

- dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. *Nat Med.* **13**, 1050-1059
- (25) Frey, B., Rubner, Y., Kulzer, L., Werthmüller, N., Weiss, E.-M., Fietkau, R., and Gaipl, U. (2014) Antitumor immune responses induced by ionizing irradiation and further immune stimulation. *Cancer Immunol Immunother.* **63**, 29-36
 - (26) Park, B., Yee, C., and Lee, K.-M. (2014) The Effect of Radiation on the Immune Response to Cancers. *International Journal of Molecular Sciences.* **15**, 927-943
 - (27) Zitvogel, L., Apetoh, L., Ghiringhelli, F., and Kroemer, G. (2008) Immunological aspects of cancer chemotherapy. *Nat Rev Immunol.* **8**, 59-73
 - (28) Ramakrishnan, R., Assudani, D., Nagaraj, S., Hunter, T., Cho, H.-I., Antonia, S., Altioek, S., Celis, E., and Gabilovich, D.I. (2010) Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice. *The Journal of Clinical Investigation.* **120**, 1111-1124
 - (29) Ghiringhelli, F., and Apetoh, L. (2014) The interplay between the immune system and chemotherapy: emerging methods for optimizing therapy. *Expert Review of Clinical Immunology.* **10**, 19-30
 - (30) Brahmer, J.R., Tykodi, S.S., Chow, L.Q.M., Hwu, W.-J., Topalian, S.L., Hwu, P., Drake, C.G., Camacho, L.H., Kauh, J., Odunsi, K., Pitot, H.C., Hamid, O., Bhatia, S., Martins, R., Eaton, K., Chen, S., Salay, T.M., Alaparthi, S., Grosso, J.F., Korman, A.J., Parker, S.M., Agrawal, S., Goldberg, S.M., Pardoll, D.M., Gupta, A., and Wigginton, J.M. (2012) Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer. *New England Journal of Medicine.* **366**, 2455-2465
 - (31) Topalian, S.L., Hodi, F.S., Brahmer, J.R., Gettinger, S.N., Smith, D.C., McDermott, D.F., Powderly, J.D., Carvajal, R.D., Sosman, J.A., Atkins, M.B., Leming, P.D., Spigel, D.R., Antonia, S.J., Horn, L., Drake, C.G., Pardoll, D.M., Chen, L., Sharfman, W.H., Anders, R.A., Taube, J.M., McMiller, T.L., Xu, H., Korman, A.J., Jure-Kunkel, M., Agrawal, S., McDonald, D., Kollia, G.D., Gupta, A., Wigginton, J.M., and Sznol, M. (2012) Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer. *New England Journal of Medicine.* **366**, 2443-2454
 - (32) Matsui, S., Ahlers, J.D., Vortmeyer, A.O., Terabe, M., Tsukui, T., Carbone, D.P., Liotta, L.A., and Berzofsky, J.A. (1999) A Model for CD8+ CTL Tumor Immunosurveillance and Regulation of Tumor Escape by CD4 T Cells Through an Effect on Quality of CTL. *The Journal of Immunology.* **163**, 184-193
 - (33) Halpern, J.N., Cohen, E., Mekori, T., Beny, A.N., Kuten, A., Rosenblatt, E.A., and Robinson, E. (1991) The effect of in vitro irradiation on human NK cell activity. A preliminary report. *J Med.* **22**, 243-254
 - (34) Sonn, C.H., Choi, J.R., Kim, T.-J., Yu, Y.-B., Kim, K., Shin, S.C., Park, G.-H., Shirakawa, T., Kim, H.S., and Lee, K.-M. (2012) Augmentation of natural cytotoxicity by chronic low-dose ionizing radiation in murine natural killer cells primed by IL-2. *Journal of Radiation Research.* **53**, 823-829
 - (35) Bryceon, Y.T., March, M.E., Ljunggren, H.-G., and Long, E.O. (2006) Activation, coactivation, and costimulation of resting human natural killer cells. *Immunological Reviews.* **214**, 73-91
 - (36) Smyth, M.J., Swann, J., Cretney, E., Zerafa, N., Yokoyama, W.M., and Hayakawa, Y. (2005) NKG2D function protects the host from tumor initiation. *The Journal of Experimental Medicine.* **202**, 583-588
 - (37) Guerra, N., Tan, Y.X., Joncker, N.T., Choy, A., Gallardo, F., Xiong, N., Knoblaugh, S., Cado, D., Greenberg, N.R., and Raulet, D.H. (2008) NKG2D-Deficient Mice Are Defective in Tumor Surveillance in Models of Spontaneous Malignancy. *Immunity.* **28**, 571-580
 - (38) Pende, D., Parolini, S., Pessino, A., Sivori, S., Augugliaro, R., Morelli, L., Marcenaro, E., Accame, L., Malaspina, A., Biassoni, R., Bottino, C., Moretta, L., and Moretta, A. (1999) Identification and Molecular Characterization of Nkp30, a Novel Triggering Receptor Involved in Natural Cytotoxicity Mediated by Human Natural Killer Cells. *The Journal of Experimental Medicine.* **190**, 1505-1516
 - (39) Matta, J., Baratin, M., Chiche, L., Forel, J.-M., Cognet, C., Thomas, G., Farnarier, C., Piperoglou, C., Papazian, L., Chaussabel, D., Ugolini, S., Vély, F., and Vivier, E. (2013) Induction of B7-H6,

- a ligand for the natural killer cell–activating receptor NKp30, in inflammatory conditions. *Blood*. **122**, 394-404
- (40) Fiegler, N., Textor, S., Arnold, A., Rölle, A., Oehme, I., Breuhahn, K., Moldenhauer, G., Witzens-Harig, M., and Cerwenka, A. (2013) Downregulation of the activating NKp30 ligand B7-H6 by HDAC inhibitors impairs tumor cell recognition by NK cells. *Blood*. **122**, 684-693

FIGURE 1. Specificity of anti-B7-H6 antibody. (A) CHO-K1 cells were transfected with pcDNA3-B7-H6 and then were harvested 24 h later. B7-H6 expression was analyzed by Western blotting. (B) HEK293 cells were transfected with pcDNA3-B7-H6 or pcDNA3-myc-B7-H6 and then were harvested 24 h later. B7-H6 and myc-tag expressions were analyzed by Western blotting. (C-D) HEK293 cells were transfected with pcDNA3-B7-H6 or pcDNA3-myc-B7-H6 and then were harvested 24 h later. myc-tag (C) and B7-H6 (D) expressions were analyzed by Flow cytometry.

FIGURE 2. B7-H6 is widely expressed in tumor cell lines. (A) B7-H6 expression in human tumor cell lines was analyzed by real-time PCR. (B) B7-H6 expression in human tumor cells was analyzed by Western blotting.

FIGURE 3. B7-H6 expression in tumor cells correlates to their susceptibility to NK killing. (A-B) HEK293 cells were transduced with lentivirus delivering scramble shRNA (shScr) or shRNA targeting B7-H6 (shB7-H6-1, shB7-H6-2), and B7-H6 expression was then analyzed by real-time PCR (A) and Western blotting (B). (C) Lysis of HEK293 cells transduced with shScr, shB7-H6-1 or shB7-H6-2 by NK-92 cells was determined in a 4 h cytotoxicity assay. (D) Lysis of K562, HL60, U937 or HeLa cells transduced with shScr, shB7-H6-1 or shB7-H6-2 by NK-92 cells was determined in a 4 h cytotoxicity assay.

FIGURE 4. Cisplatin treatment increases B7-H6 expression and sensitizes target cells to NK cell cytotoxicity. (A) HEK293 cells were stimulated with 10 μ M, 20 μ M or 40 μ M cisplatin for the indicated times. B7-H6 expression was analyzed by real-time PCR. (B) HEK293 cells were stimulated with various doses of cisplatin for 24 h. B7-H6 expression was analyzed by real-time PCR. (C) HEK293 cells were treated with various doses of cisplatin for 48 h. B7-H6 expression was analyzed by Western blotting. (D) HEK293 cells were treated with 40 μ M cisplatin for 48 h. Cell surface B7-H6 expression was analyzed by Flow cytometry. (E) HL60 cells were stimulated with various doses of cisplatin for 48 h. B7-H6 expression was analyzed by Western blotting. (F) HL60 cells were treated with 40 μ M cisplatin for 48 h. B7-H6 expression on cell surface was analyzed by Flow cytometry. (G) HEK293 cells were stimulated with 20 μ M or 40 μ M cisplatin for 48 h and then subjected to NK-92-mediated lysis. (H) HEK293/shScr, HEK293/shB7-H6-1 and HEK293/shB7-H6-2 were stimulated with 40 μ M cisplatin for 48 h or not and then subjected to NK-92-mediated lysis.

FIGURE 5. 5-FU treatment increases B7-H6 expression and sensitizes target cells to NK cell cytotoxicity. (A) HEK293 cells were stimulated with 10 μ M, 20 μ M or 40 μ M 5-FU for the indicated times. B7-H6 expression was analyzed by real-time PCR. (B) HEK293 cells were stimulated with various doses of 5-FU for 48 h. B7-H6 expression was analyzed by real-time PCR. (C) HEK293 cells were treated with various doses of 5-FU for 48 h. B7-H6 expression was analyzed by Western blotting. (D) HEK293 cells were treated with 40 μ M 5-FU for the indicated times. Cell surface B7-H6 expression was analyzed by Flow cytometry. (E) HL60 cells were stimulated with various doses of 5-FU for 48 h. B7-H6 expression was analyzed by Western blotting. (F) HL60 cells were treated with 40 μ M 5-FU for 48 h. B7-H6 expression on cell surface was analyzed by Flow cytometry. (G) HEK293 cells were stimulated with 40 μ M or 100 μ M 5-FU for 48 h and then subjected to NK-92-mediated lysis. (H) HEK293/shScr, HEK293/shB7-H6-1 and HEK293/shB7-H6-2 were stimulated with 100 μ M 5-FU for 48 h or not and then subjected to NK-92-mediated lysis.

FIGURE 6. Irradiation increases B7-H6 expression and makes target cells more sensitive to NK cell cytotoxicity. (A) HEK293 cells were treated with 2 Gy, 4 Gy or 8 Gy irradiation and then cultured for the indicated times. B7-H6 expression was analyzed by real-time PCR. (B) HEK293 cells were treated with various doses of irradiation and then cultured for 24 h. B7-H6 expression was analyzed by real-time PCR. (C) HEK293 cells were treated with 8 Gy irradiation and then cultured for the indicated times. B7-H6 expression was analyzed by Western blotting. (D) HEK293 cells were exposed to various doses of irradiation and then cultured for 24 h. B7-H6 expression was analyzed by Western blotting. (E) HEK293 cells were treated with 8 Gy irradiation and then cultured for 24 h. B7-H6 expression was analyzed by Flow cytometry. (F) HL60 cells were treated with 8 Gy irradiation and then cultured for the indicated times. B7-H6 expression was analyzed by Western blotting. (G) HL60 cells were treated with various doses of irradiation and then cultured for 48 h. B7-H6 expression was analyzed by Western blotting. (H) HL60 cells were exposed to 8 Gy irradiation and then cultured for 48 h. B7-H6 expression on cell surface analyzed by Flow cytometry. (I) HEK293 cells were treated with 0, 4 Gy or 8 Gy irradiation, cultured for 24 h and subjected to NK-92-mediated lysis. (J) HEK293/shScr, HEK293/shB7-H6-1 and HEK293/shB7-H6-2 were treated with 8 Gy irradiation or not, then cultured for 24 h and subjected to NK-92-mediated lysis.

FIGURE 7. Non-lethal heat shock increases B7-H6 expression and makes target cells more sensitive to NK cell cytotoxicity. (A, B) HEK293 cells were exposed to 42°C for 30 min and then cultured at 37°C for the indicated times. B7-H6 expression was analyzed by real-time PCR (A), Western blotting (B). HEK293 cells were exposed to 42°C for 30 min and then cultured at 37°C for 12 h and B7-H6 expression was analyzed by Flow cytometry (C). (D) HL60 cells were exposed to 42°C for 30 min and then cultured at 37°C for the indicated times. B7-H6 expression was analyzed by Western blotting. (E) HL60 cells were exposed to 42°C for 30 min and then cultured at 37°C for 12 h. B7-H6 expression on cell surface was analyzed by Flow cytometry. (F) HEK293 cells were incubated at 42°C for 30 min, cultured at 37°C for 11 h and then subjected to NK-92-mediated lysis. (G) HEK293/shScr, HEK293/shB7-H6-1 and HEK293/shB7-H6-2 were exposed to 42°C for 30 min or not, then cultured at 37°C for 11 h and subjected to NK-92-mediated lysis.

FIGURE 8. TNF- α treatment increases B7-H6 expression and sensitizes target cells to NK cell cytotoxicity. (A) HEK293 cells were stimulated with 10 ng/ml, 25 ng/ml or 50 ng/ml TNF- α for the indicated times. B7-H6 expression was analyzed by real-time PCR. (B) HEK293 cells were stimulated with various doses of TNF- α for 72 h. B7-H6 expression was analyzed by real-time PCR. (C) HEK293 cells were treated with 50 ng/ml TNF- α for the indicated times. B7-H6 expression was analyzed by Western blotting. (D) HEK293 cells were treated with various doses of TNF- α for 72 h. B7-H6 expression was analyzed by Western blotting. (E) HEK293 cells were treated with 50 ng/ml TNF- α for 48 h. B7-H6 expression was analyzed by Flow cytometry. (F) HL60 cells were stimulated with 50 ng/ml TNF- α for the indicated times. B7-H6 expression was analyzed by Western blotting. (G) HL60 cells were stimulated with various doses of TNF- α for 48 h. B7-H6 expression was analyzed by Western blotting. (H) HL60 cells were treated with 50 ng/ml TNF- α for 48 h. B7-H6 expression on cell surface was analyzed by Flow cytometry. (I) HEK293 cells were stimulated with 5 ng/ml, 25 ng/ml or 50 ng/ml TNF- α for 72 h and then subjected to NK-92-mediated lysis. (J) HEK293/shScr, HEK293/shB7-H6-1 and HEK293/shB7-H6-2 were stimulated with 50 ng/ml TNF- α for 72 h or not and then subjected to NK-92-mediated lysis.

FIGURE 9. Anti-NKp30 and anti-NKG2D blocking antibodies treatment dampens NK cell-mediated cytotoxicity to tumor cells. (A) HEK293 cells were stimulated with 40 μ M cisplatin for 48 h and then subjected to NKG-mediated cytotoxicity in the presence of anti-NKp30 mAb and/or anti-NKG2D mAb. (B) HEK293 cells were incubated at 42°C for 30 min, then cultured at 37°C for 11 h, and finally subjected to NKG-mediated lysis in the presence of anti-NKp30 mAb and/or anti-NKG2D mAb. (C) HEK293 cells were stimulated with 50 ng/ml TNF- α for 48 h and then subjected to NKG-mediated lysis in the presence of anti-NKp30 mAb and/or anti-NKG2D mAb.

Figure 1




Figure 2




Figure 3




Figure 4




Figure 5




Figure 6




Figure 7




Figure 8






Figure 9



Immunology:

Tumor therapeutics work as stress inducers to enhance tumor sensitivity to NK cell cytotoxicity by upregulating NKp30 ligand B7-H6

Guoshuai Cao, Jian Wang, Xiaodong Zheng,
Haiming Wei, Zhigang Tian and Rui Sun
J. Biol. Chem. published online October 15, 2015



Access the most updated version of this article at doi: [10.1074/jbc.M115.674010](https://doi.org/10.1074/jbc.M115.674010)

Find articles, minireviews, Reflections and Classics on similar topics on the [JBC Affinity Sites](#).

Alerts:

- [When this article is cited](#)
- [When a correction for this article is posted](#)

[Click here](#) to choose from all of JBC's e-mail alerts

This article cites 0 references, 0 of which can be accessed free at
<http://www.jbc.org/content/early/2015/10/15/jbc.M115.674010.full.html#ref-list-1>